vs
BioNexus Gene Lab Corp（BGLC）与RadNet, Inc.（RDNT）财务数据对比。点击上方公司名可切换其他公司
RadNet, Inc.的季度营收约是BioNexus Gene Lab Corp的1132.2倍（$547.7M vs $483.8K）。RadNet, Inc.净利率更高（-0.1% vs -214.2%，领先214.1%）。RadNet, Inc.同比增速更快（14.8% vs -80.8%）。过去两年RadNet, Inc.的营收复合增速更高（12.6% vs -54.9%）
BioNexus Gene Lab Corp是一家生物技术企业，主营分子诊断检测、基因分析及相关生命科学解决方案，服务客户涵盖医疗机构、科研机构及个人用户，核心市场主要覆盖东南亚地区。
RadNet是美国领先的放射医疗服务企业，总部位于加利福尼亚州洛杉矶，是美国规模最大的独立固定地址诊断影像中心运营商，按网点数量及年度影像业务收入计均居行业首位。截至2025年，该公司在全美8个州持有或运营超400家影像中心，提供门诊诊断影像服务。
BGLC vs RDNT — 直观对比
营收规模更大
RDNT
是对方的1132.2倍
$483.8K
营收增速更快
RDNT
高出95.6%
-80.8%
净利率更高
RDNT
高出214.1%
-214.2%
两年增速更快
RDNT
近两年复合增速
-54.9%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $483.8K | $547.7M |
| 净利润 | $-1.0M | $-597.0K |
| 毛利率 | -0.8% | — |
| 营业利润率 | -213.5% | 5.1% |
| 净利率 | -214.2% | -0.1% |
| 营收同比 | -80.8% | 14.8% |
| 净利润同比 | -197.5% | -111.2% |
| 每股收益（稀释后） | — | $0.00 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BGLCRDNT
| Q4 25 | $483.8K | $547.7M | ||
| Q3 25 | $2.5M | $522.9M | ||
| Q2 25 | $2.3M | $498.2M | ||
| Q1 25 | $2.1M | $471.4M | ||
| Q4 24 | $2.5M | $477.1M | ||
| Q3 24 | $2.6M | $461.1M | ||
| Q2 24 | $2.0M | $459.7M | ||
| Q1 24 | $2.4M | $431.7M |
净利润BGLCRDNT
| Q4 25 | $-1.0M | $-597.0K | ||
| Q3 25 | $-709.0K | $5.4M | ||
| Q2 25 | $-616.2K | $14.5M | ||
| Q1 25 | $-623.3K | $-37.9M | ||
| Q4 24 | $-348.3K | $5.3M | ||
| Q3 24 | $-1.3M | $3.2M | ||
| Q2 24 | $199.1K | $-3.0M | ||
| Q1 24 | $-103.8K | $-2.8M |
毛利率BGLCRDNT
| Q4 25 | -0.8% | — | ||
| Q3 25 | 14.8% | — | ||
| Q2 25 | 16.3% | — | ||
| Q1 25 | 16.1% | — | ||
| Q4 24 | 12.3% | — | ||
| Q3 24 | 12.4% | — | ||
| Q2 24 | 14.6% | — | ||
| Q1 24 | 15.3% | — |
营业利润率BGLCRDNT
| Q4 25 | -213.5% | 5.1% | ||
| Q3 25 | -27.6% | 5.2% | ||
| Q2 25 | -27.0% | 6.2% | ||
| Q1 25 | -28.9% | -5.1% | ||
| Q4 24 | -16.5% | 5.1% | ||
| Q3 24 | -50.9% | 7.4% | ||
| Q2 24 | 13.1% | 7.6% | ||
| Q1 24 | -3.3% | 2.6% |
净利率BGLCRDNT
| Q4 25 | -214.2% | -0.1% | ||
| Q3 25 | -27.9% | 1.0% | ||
| Q2 25 | -27.3% | 2.9% | ||
| Q1 25 | -29.2% | -8.0% | ||
| Q4 24 | -13.8% | 1.1% | ||
| Q3 24 | -51.1% | 0.7% | ||
| Q2 24 | 10.1% | -0.6% | ||
| Q1 24 | -4.4% | -0.6% |
每股收益（稀释后）BGLCRDNT
| Q4 25 | — | $0.00 | ||
| Q3 25 | $-0.40 | $0.07 | ||
| Q2 25 | $-0.34 | $0.19 | ||
| Q1 25 | $-0.04 | $-0.51 | ||
| Q4 24 | $0.55 | $0.08 | ||
| Q3 24 | $-0.75 | $0.04 | ||
| Q2 24 | $0.11 | $-0.04 | ||
| Q1 24 | $-0.01 | $-0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.5M | $767.2M |
| 总债务越低越好 | — | $1.1B |
| 股东权益账面价值 | $8.6M | $1.1B |
| 总资产 | $9.3M | $3.8B |
| 负债/权益比越低杠杆越低 | — | 1.00× |
8季度趋势，按日历期对齐
现金及短期投资BGLCRDNT
| Q4 25 | $2.5M | $767.2M | ||
| Q3 25 | — | $804.7M | ||
| Q2 25 | — | $833.2M | ||
| Q1 25 | — | $717.3M | ||
| Q4 24 | $2.9M | $740.0M | ||
| Q3 24 | — | $748.9M | ||
| Q2 24 | — | $741.7M | ||
| Q1 24 | — | $527.0M |
总债务BGLCRDNT
| Q4 25 | — | $1.1B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.0B | ||
| Q4 24 | — | $1.0B | ||
| Q3 24 | — | $1.0B | ||
| Q2 24 | — | $1.0B | ||
| Q1 24 | — | $834.6M |
股东权益BGLCRDNT
| Q4 25 | $8.6M | $1.1B | ||
| Q3 25 | $6.8M | $1.1B | ||
| Q2 25 | $7.5M | $932.3M | ||
| Q1 25 | $7.8M | $898.1M | ||
| Q4 24 | $8.3M | $902.3M | ||
| Q3 24 | $9.4M | $895.3M | ||
| Q2 24 | $9.5M | $881.0M | ||
| Q1 24 | $9.3M | $873.0M |
总资产BGLCRDNT
| Q4 25 | $9.3M | $3.8B | ||
| Q3 25 | $7.6M | $3.7B | ||
| Q2 25 | $9.4M | $3.5B | ||
| Q1 25 | $9.5M | $3.3B | ||
| Q4 24 | $10.4M | $3.3B | ||
| Q3 24 | $11.0M | $3.3B | ||
| Q2 24 | $11.1M | $3.2B | ||
| Q1 24 | $11.2M | $3.0B |
负债/权益比BGLCRDNT
| Q4 25 | — | 1.00× | ||
| Q3 25 | — | 1.04× | ||
| Q2 25 | — | 1.18× | ||
| Q1 25 | — | 1.12× | ||
| Q4 24 | — | 1.13× | ||
| Q3 24 | — | 1.14× | ||
| Q2 24 | — | 1.17× | ||
| Q1 24 | — | 0.96× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $961.1K | $84.2M |
| 自由现金流经营现金流 - 资本支出 | $960.1K | — |
| 自由现金流率自由现金流/营收 | 198.5% | — |
| 资本支出强度资本支出/营收 | 0.2% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-1.9M | — |
8季度趋势，按日历期对齐
经营现金流BGLCRDNT
| Q4 25 | $961.1K | $84.2M | ||
| Q3 25 | $-1.2M | $52.8M | ||
| Q2 25 | $-737.9K | $120.3M | ||
| Q1 25 | $-824.1K | $41.5M | ||
| Q4 24 | $219.2K | $42.5M | ||
| Q3 24 | $-1.6M | $57.4M | ||
| Q2 24 | $-672.3K | $116.0M | ||
| Q1 24 | $-37.2K | $17.1M |
自由现金流BGLCRDNT
| Q4 25 | $960.1K | — | ||
| Q3 25 | $-1.2M | — | ||
| Q2 25 | $-759.4K | — | ||
| Q1 25 | $-833.1K | — | ||
| Q4 24 | $215.2K | — | ||
| Q3 24 | $-1.8M | — | ||
| Q2 24 | $-674.1K | — | ||
| Q1 24 | $-59.1K | — |
自由现金流率BGLCRDNT
| Q4 25 | 198.5% | — | ||
| Q3 25 | -48.9% | — | ||
| Q2 25 | -33.6% | — | ||
| Q1 25 | -39.0% | — | ||
| Q4 24 | 8.5% | — | ||
| Q3 24 | -68.5% | — | ||
| Q2 24 | -34.1% | — | ||
| Q1 24 | -2.5% | — |
资本支出强度BGLCRDNT
| Q4 25 | 0.2% | — | ||
| Q3 25 | 0.2% | — | ||
| Q2 25 | 0.9% | — | ||
| Q1 25 | 0.4% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 7.6% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.9% | — |
现金转化率BGLCRDNT
| Q4 25 | — | — | ||
| Q3 25 | — | 9.75× | ||
| Q2 25 | — | 8.33× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 7.96× | ||
| Q3 24 | — | 17.89× | ||
| Q2 24 | -3.38× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BGLC
暂无分部数据
RDNT
| Commercial Insurance1 | $301.0M | 55% |
| Medicare1 | $129.2M | 24% |
| Capitation Arrangements | $31.9M | 6% |
| Health Care Other | $20.4M | 4% |
| Digital Health | $16.4M | 3% |
| Other | $15.2M | 3% |
| Medicaid1 | $14.0M | 3% |
| Workers Compensation Personal Injury1 | $12.3M | 2% |
| Health Care Management Service | $7.5M | 1% |
